Erica Moretti

1.0k total citations
30 papers, 645 citations indexed

About

Erica Moretti is a scholar working on Oncology, Cancer Research and Molecular Biology. According to data from OpenAlex, Erica Moretti has authored 30 papers receiving a total of 645 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Oncology, 16 papers in Cancer Research and 11 papers in Molecular Biology. Recurrent topics in Erica Moretti's work include HER2/EGFR in Cancer Research (13 papers), Advanced Breast Cancer Therapies (10 papers) and Breast Cancer Treatment Studies (10 papers). Erica Moretti is often cited by papers focused on HER2/EGFR in Cancer Research (13 papers), Advanced Breast Cancer Therapies (10 papers) and Breast Cancer Treatment Studies (10 papers). Erica Moretti collaborates with scholars based in Italy, United States and Australia. Erica Moretti's co-authors include Angelo Di Leo, Libero Santarpia, Ilenia Migliaccio, Laura Biganzoli, Robert C. Bast, Aman U. Buzdar, Ju‐Yeon Kim, George A. Călin, Luca Malorni and Francisco J. Esteva and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Clinical Cancer Research.

In The Last Decade

Erica Moretti

29 papers receiving 635 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Erica Moretti Italy	13	383	373	273	161	32	30	645
Martina Vetter Germany	14	384 1.0×	341 0.9×	206 0.8×	79 0.5×	23 0.7×	44	629
Daniela Cianniello Italy	8	206 0.5×	179 0.5×	281 1.0×	212 1.3×	43 1.3×	13	528
Luis J. Schwarz Peru	10	511 1.3×	317 0.8×	319 1.2×	97 0.6×	34 1.1×	17	808
Ilenia Segatto Italy	14	290 0.8×	198 0.5×	251 0.9×	99 0.6×	29 0.9×	23	536
Qing-Yun Chong Singapore	14	280 0.7×	184 0.5×	140 0.5×	109 0.7×	31 1.0×	16	472
Yunming Tian China	14	279 0.7×	211 0.6×	198 0.7×	127 0.8×	18 0.6×	24	677
Enrique Alvarez Sotomayor United States	7	411 1.1×	289 0.8×	220 0.8×	78 0.5×	38 1.2×	9	590
Sandy D. Markowitz United States	2	528 1.4×	404 1.1×	221 0.8×	59 0.4×	13 0.4×	2	735
Yanyang Wang China	14	552 1.4×	275 0.7×	163 0.6×	78 0.5×	14 0.4×	24	727
Elisa Caiola Italy	15	450 1.2×	208 0.6×	227 0.8×	164 1.0×	19 0.6×	33	621

Countries citing papers authored by Erica Moretti

Since Specialization

Citations

This map shows the geographic impact of Erica Moretti's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Erica Moretti with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Erica Moretti more than expected).

Fields of papers citing papers by Erica Moretti

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Erica Moretti. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Erica Moretti. The network helps show where Erica Moretti may publish in the future.

Co-authorship network of co-authors of Erica Moretti

This figure shows the co-authorship network connecting the top 25 collaborators of Erica Moretti. A scholar is included among the top collaborators of Erica Moretti based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Erica Moretti. Erica Moretti is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Nardone, Agostina, Nicola Casiraghi, Francesca Galardi, et al.. (2025). Enabling sensitive and precise detection of ctDNA through somatic copy number aberrations in breast cancer. npj Breast Cancer. 11(1). 25–25. 2 indexed citations

Migliaccio, Ilenia, Dario Romagnoli, Francesca Galardi, et al.. (2024). Mutational Analysis of Circulating Tumor DNA in Patients With Estrogen Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer Receiving Palbociclib: Results From the TREnd Trial. JCO Precision Oncology. 8(8). e2300285–e2300285. 4 indexed citations

Romagnoli, Dario, Agostina Nardone, Francesca Galardi, et al.. (2023). MIMESIS: minimal DNA-methylation signatures to quantify and classify tumor signals in tissue and cell-free DNA samples. Briefings in Bioinformatics. 24(2). 1 indexed citations

Benelli, Matteo, Antonio Nardone, Francesca Galardi, et al.. (2023). 2272P Minimal DNA-methylation (DNAm) signatures for non-invasive tumor-agnostic estimation of tumor content (TC) and molecular subtype in patients (pts) with metastatic breast cancer (mBC). Annals of Oncology. 34. S1166–S1166. 1 indexed citations

Risi, Emanuela, C. Lisanti, Alessia Vignoli, et al.. (2022). Risk assessment of disease recurrence in early breast cancer: A serum metabolomic study focused on elderly patients. Translational Oncology. 27. 101585–101585. 2 indexed citations

Vignoli, Alessia, Emanuela Risi, Amelia McCartney, et al.. (2021). Precision Oncology via NMR-Based Metabolomics: A Review on Breast Cancer. International Journal of Molecular Sciences. 22(9). 4687–4687. 28 indexed citations

Galardi, Francesca, Francesca De Luca, Chiara Biagioni, et al.. (2021). Circulating tumor cells and palbociclib treatment in patients with ER-positive, HER2-negative advanced breast cancer: results from a translational sub-study of the TREnd trial. Breast Cancer Research. 23(1). 38–38. 25 indexed citations

McCartney, Amelia, Martina Bonechi, Francesca De Luca, et al.. (2020). Plasma Thymidine Kinase Activity as a Biomarker in Patients with Luminal Metastatic Breast Cancer Treated with Palbociclib within the TREnd Trial. Clinical Cancer Research. 26(9). 2131–2139. 37 indexed citations

Sanna, Giuseppina, Marta Pestrin, Erica Moretti, et al.. (2020). A Dose-finding Study of Metronomic Oral Vinorelbine in Combination With Oral Cyclophosphamide and Bevacizumab in Patients With Advanced Breast Cancer. Clinical Breast Cancer. 21(4). e332–e339. 3 indexed citations

10.

Rossi, Lorenzo, Chiara Biagioni, Amelia McCartney, et al.. (2019). Clinical outcomes after palbociclib with or without endocrine therapy in postmenopausal women with hormone receptor positive and HER2-negative metastatic breast cancer enrolled in the TREnd trial. Breast Cancer Research. 21(1). 71–71. 20 indexed citations

11.

Rossi, Lorenzo, Amelia McCartney, Irene De Santo, et al.. (2019). The optimal duration of adjuvant endocrine therapy in early luminal breast cancer: A concise review. Cancer Treatment Reviews. 74. 29–34. 15 indexed citations

12.

Rossi, Lorenzo, Chiara Biagioni, Amelia McCartney, et al.. (2018). Platinum-based Agent and Fluorouracil in Metastatic Breast Cancer: A Retrospective Monocentric Study with a Review of the Literature. Anticancer Research. 38(8). 4839–4845. 7 indexed citations

13.

Turner, Natalie, Laura Biganzoli, Luca Malorni, et al.. (2013). Adjuvant Chemotherapy: Which Patient? What Regimen?. American Society of Clinical Oncology Educational Book. 3–8. 2 indexed citations

14.

Turner, Natalie, Laura Biganzoli, Luca Malorni, et al.. (2013). The continued evidence from overviews: What is the clinical utility?. The Breast. 22. S8–S11. 1 indexed citations

15.

Turner, Natalie, Erica Moretti, Ilenia Migliaccio, et al.. (2013). Targeting triple negative breast cancer: Is p53 the answer?. Cancer Treatment Reviews. 39(5). 541–550. 106 indexed citations

16.

Oakman, Catherine, Erica Moretti, Giulia Pacini, Libero Santarpia, & Angelo Di Leo. (2011). Triple negative breast cancer: a heterogeneous subgroup denned by what it is not. European Journal of Cancer. 47. S370–S372. 9 indexed citations

17.

Oakman, Catherine, Erica Moretti, Francesca Galardi, et al.. (2011). Adjuvant systemic treatment for individual patients with triple negative breast cancer. The Breast. 20. S135–S141. 14 indexed citations

18.

Oakman, Catherine, Erica Moretti, Francesca Galardi, Libero Santarpia, & Angelo Di Leo. (2009). The role of topoisomerase IIα and HER-2 in predicting sensitivity to anthracyclines in breast cancer patients. Cancer Treatment Reviews. 35(8). 662–667. 25 indexed citations

19.

Moretti, Erica, Catherine Oakman, & Angelo Di Leo. (2009). Predicting anthracycline benefit: have we made any progress?. Current Opinion in Oncology. 21(6). 507–515. 9 indexed citations

20.

Biganzoli, Laura, et al.. (2008). Taxanes in the elderly: Can we gain as much and be less toxic?. Critical Reviews in Oncology/Hematology. 70(3). 262–271. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact